Использование лисенила-форте и метерголина в лечении гиперпролактинемического гипогонадизмастатья
Статья опубликована в журнале из списка RSCI Web of Science
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 11 ноября 2019 г.
Аннотация:The paper is concerned with a study of the effectiveness of lysenyl-forte (Hemapol, Czechoslovakia) and methergoline (Carlo Erba, Italy) for therapy of patients with different types of hyperprolactinemic hypogonadism. Altogether 49 patients were investigated, of them 33 received lysenyl-forte at a dose of 0.6 mg/day and 16-methergoline at a dose of 12 mg/day for 3 months. A degree of galactorrhea, a menstrual cycle and the blood level of prolactin were assessed before and after therapy. A prolactin inhibiting effect of both drugs comparable with that of bromocriptine was noted. However a clinical effect and good tolerance were more frequently observed in this sampling in lysenyl therapy.